Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2012, Article ID 523842, 7 pages
http://dx.doi.org/10.1155/2012/523842
Review Article

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas

S. C. Oncohematology, Perugia University, S. Maria, 05100 Terni, Italy

Received 16 February 2012; Revised 29 March 2012; Accepted 16 April 2012

Academic Editor: Umberto Vitolo

Copyright © 2012 Marco Gunnellini and Lorenzo Falchi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Kaunshansky, M. Lichtman, E. Beutler, T. Kipps, J. Prchal, and U. Seligsohn, Williams Hematology, McGrow-Hill, 8th edition, 2011.
  2. S. H. Swerdlow, E. Campo, N. L. Harris et al., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, WHO Press, 4th edition, 2008.
  3. S. A. van de Schans, E. W. Steyerberg, M. R. Nijziel, G. J. Creemers, M. L. Janssen-Heijnen, and D. J. van Spronsen, “Validation, revision and extension of the follicular lymphoma international prognostic index (FLIPI) in a population-based setting,” Annals of Oncology, vol. 20, no. 10, pp. 1697–1702, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. C. H. Geisler, A. Kolstad, A. Laurell et al., “The mantle cell lymphoma international prognostic index (MIPI) is superior to the international prognostic index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT),” Blood, vol. 115, no. 8, pp. 1530–1533, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. L. H. Sehn, B. Berry, M. Chhanabhai et al., “The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP,” Blood, vol. 109, no. 5, pp. 1857–1861, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Schulz, J. E. Bohlius, S. Trelle et al., “Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis,” Journal of the National Cancer Institute, vol. 99, no. 9, pp. 706–714, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Sachanas, G. A. Pangalis, T. P. Vassilakopoulos et al., “Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen,” Leukemia & Lymphoma, vol. 52, no. 3, pp. 387–393, 2011. View at Google Scholar
  8. M. J. Kersten, “Radioimmunotherapy in follicular lymphoma: some like it hot...,” Transfusion and Apheresis Science, vol. 44, no. 2, pp. 173–178, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. K. Gopal, J. G. Rajendran, T. A. Gooley et al., “High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults ≥ 60 years old with relapsed or refractory B-cell lymphoma,” Journal of Clinical Oncology, vol. 25, no. 11, pp. 1396–1402, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. P. H. Wiernik, I. S. Lossos, J. M. Tuscano et al., “Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 26, no. 30, pp. 4952–4957, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. T. E. Witzig, P. H. Wiernik, T. Moore et al., “Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 27, no. 32, pp. 5404–5409, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. C. B. Reeder, T. E. Witzig, P. L. Zinzani et al., “Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results from an international study (NHL-003),” Journal of Clinical Oncology, vol. 27, no. 15, supplement, abstract e19504, 2009. View at Google Scholar
  13. T. M. Habermann, I. S. Lossos, G. Justice et al., “Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma,” British Journal of Haematology, vol. 145, no. 3, pp. 344–349, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. T. E. Witzig, J. M. Vose, P. L. Zinzani et al., “An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma,” Annals of Oncology, vol. 22, no. 7, pp. 1622–1627, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Roussel, T. Facon, P. Moreau, J. L. Harousseau, and M. Attal, “Firstline treatment and maintenance in newly diagnosed multiple myeloma patients,” Recent Results in Cancer Research, vol. 183, pp. 189–206, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Gentile, A. G. Recchia, E. Vigna et al., “Lenalidomide in the treatment of chronic lymphocytic leukemia,” Expert Opinion on Investigational Drugs, vol. 20, no. 2, pp. 273–286, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Dueck, N. Chua, A. Prasad et al., “Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-hodgkin lymphoma,” Cancer, vol. 116, no. 19, pp. 4541–4548, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. Z. Qian, L. Zhang, Z. Cai et al., “Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo,” Leukemia Research, vol. 35, no. 3, pp. 380–386, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. A. A. Chanan-Khan and B. D. Cheson, “Lenalidomide for the treatment of B-cell malignancies,” Journal of Clinical Oncology, vol. 26, no. 9, pp. 1544–1552, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. V. Kotla, S. Goel, S. Nischal et al., “Mechanism of action of lenalidomide in hematological malignancies,” Journal of Hematology and Oncology, vol. 2, article 36, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Reddy, F. J. Hernandez-Ilizaliturri, G. Deeb et al., “Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo,” British Journal of Haematology, vol. 140, no. 1, pp. 36–45, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. A. Chanan-Khan and B. D. Cheson, “Lenalidomide for the treatment of B-cell malignancies,” Journal of Clinical Oncology, vol. 26, no. 9, pp. 1544–1552, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. D. H. Chang, N. Liu, V. Klimek et al., “Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications,” Blood, vol. 108, no. 2, pp. 618–621, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Wu, M. Adams, T. Carter et al., “Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells,” Clinical Cancer Research, vol. 14, no. 14, pp. 4650–4657, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Zhang, Z. Qian, Z. Cai et al., “Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo,” American Journal of Hematology, vol. 84, no. 9, pp. 553–559, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. P. L. Zinzani, T. E. Witzig, J. M. Vose et al., “Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results of an international study (NHL-003),” Blood, vol. 112, abstract 262, 2008. View at Google Scholar
  27. M. Wang, L. Fayad, F. Hagemeister et al., “A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy,” Journal of Clinical Oncology, vol. 25, no. 18, supplement, abstract 8030, 2007. View at Google Scholar
  28. M. Dutia, I. DeRoock, K. Chee et al., “R2: preliminary results of a phase II study of lenalidomide and rituximab in relapsed/ refractory indolent non-Hodgkin’s lymphoma (NHL),” Blood, vol. 114, abstract a1679, 2009. View at Google Scholar
  29. F. Zaja, S. De Luca, U. Vitolo et al., “Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neoangiogenic biomarkers,” Haematologica, vol. 97, no. 3, pp. 416–422, 2012. View at Publisher · View at Google Scholar
  30. V. A. Morrison, S. Jung, J. L. Johnson et al., “A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501),” Journal of Clinical Oncology, vol. 29, abstract TPS223, 2011. View at Google Scholar
  31. N. H. Fowler, P. McLaughlin, F. B. Hagemeister et al., “Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, abstract a8036, 2010. View at Google Scholar
  32. F. Samaniego, F. Hagemeister, P. Mclaughlin et al., “High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria,” Journal of Clinical Oncology, vol. 29, abstract a8030, 2011. View at Google Scholar
  33. H. Tilly, F. Morschhauser, G. A. Salles et al., “Phase I study of escalating doses of lenalidomide combined with R-CHOP (R2-CHOP) for front-line treatment of B-cell lymphomas,” Blood, vol. 118, no. 21, abstract a1632, 2011. View at Google Scholar
  34. V. P. Kenkre, W. L. Long, J. C. Eickhoff et al., “Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the wisconsin oncology network,” Leukemia & Lymphoma, vol. 52, no. 9, pp. 1675–1680, 2011. View at Google Scholar
  35. J. C. Kluin-Nelemans, E. Hoster, J. Walewski et al., “R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-alfa: outcome of the first randomized trial for elderly patients with mantle cell lymphoma,” Blood, vol. 118, abstract a439, 2011. View at Google Scholar
  36. M. Jerkeman, A. Kolstad, A. Laurell et al., “Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: the nordic lymphoma group MCL4 (LENA-BERIT) trial,” Journal of Clinical Oncology, vol. 28, no. 18, supplement, abstract a18567, 2010. View at Google Scholar
  37. T. Ahmadi, E. A. Chong, A. Gordon et al., “Phase II trial of lenalidomide—rituximab +/− dexamethasone in relapsed or refractory indolent B-cell or mantle cell lymphomas resistant to rituximab,” Blood, vol. 118, abstract a266, 2011. View at Google Scholar